Paul Toren
CHU de Québec - Université Laval · CHU de Québec-Université Laval
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paul Toren as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:58 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06018116 · A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.CHU de Quebec-Universite Laval · withdrawn · Metastatic Urothelial Carcinoma · study chair
- Ph2NCT05327647 · A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder CancerCHU de Quebec-Universite Laval · recruiting · Non-Muscle Invasive Bladder Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:58 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- 141 citationsRCR 4.1
- A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.Am J Psychiatry · 2006110 citationsRCR 3.8
- Zinc deficiency in attention-deficit hyperactivity disorder.Biol Psychiatry · 199654 citationsRCR 2.0
- Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study.J Clin Psychiatry · 200546 citationsRCR 1.5
- Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.Prog Neuropsychopharmacol Biol Psychiatry · 200230 citationsRCR 1.1
- Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry · 200528 citationsRCR 1.0
- Ondansetron treatment in patients with Tourette's syndrome.Int Clin Psychopharmacol · 199927 citationsRCR 1.0
- 25 citationsRCR 1.0
- Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.Eur Urol Oncol · 202021 citationsRCR 0.9
- Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial.Clin Cancer Res · 201819 citationsRCR 0.6